Since it was founded in 2014, Emplicure has transformed from being a company with potential and ambitions of going public to today having one drug candidate heading into clinical studies and a consumer product ready to premiere in June. A person who has been involved throughout the company’s journey is co-founder Thomas Lundqvist, who resigned as chairman of the board in April. BioStock spoke to Lundqvist about his new role and how he sees the company’s future.
Read the full article >>